🧾 What This Document Is

This is an 8-K filing from Cyclerion Therapeutics (CYCN). It contains the signed legal agreements for a major corporate transaction announced on April 1, 2026. Think of this as the "fine print" and commitments that make the headline deal official. There are three key exhibits: two Support Agreements and one Securities Purchase Agreement.

🔥 The Big Picture: A Reverse Merger

👉 In simple terms: Cyclerion Therapeutics (the "Parent") is merging with a smaller company called Korsana Biosciences. But here's the twist – after the merger, the combined company will be renamed Korsana Biosciences, Inc. This is often called a "reverse merger," where a private company (Korsana) effectively goes public by merging into a public shell (Cyclerion).

Why it matters for investors: This isn't Cyclerion buying Korsana in a traditional sense. It's more of a corporate "re-domiciling" where Korsana becomes the public entity, and Cyclerion becomes a subsidiary. The original Cyclerion business as it was known will cease to exist.

🏢 The Key Companies & Deal Mechanics

• Parent (Public Company): Cyclerion Therapeutics, Inc. (CYCN), a Massachusetts corporation.
• Company (Private Target): Korsana Biosciences, Inc., a Delaware corporation.
• Merger Structure: A two-step process:
  1. A Cyclerion subsidiary merges into Korsana, with Korsana surviving as a Cyclerion subsidiary.
  2. Immediately after, Korsana merges into a different Cyclerion subsidiary ("Second Merger Sub"), and that subsidiary survives.
• Final Result: The surviving company changes its name to Korsana Biosciences, Inc. and continues trading on the public market.

✋ The Shareholder Support Agreements (EX-10.1 & EX-10.2)

These are nearly identical contracts that lock in the votes needed to approve the merger. They create ironclad promises.

For Korsana Shareholders (EX-10.1):

• The Pledge: Major Korsana stockholders (whose names are in a confidential Appendix A) agree to vote all their shares in favor of the merger.
• The Lock-up: They are prohibited from selling or transferring their shares until the deal closes or is terminated.
• Irrevocable Proxy: If they don't vote as promised, they have already given Cyclerion the legal power (a proxy) to vote their shares for them.
• No Competing Deals: They cannot solicit or support any alternative acquisition proposals.

For Cyclerion Shareholders (EX-10.2):

• The Pledge: Major Cyclerion stockholders (also in a confidential Appendix A) agree to vote in favor of the "Parent Shareholder Matters." This likely includes approving the issuance of new Cyclerion shares for the deal and the name change.
• Same Restrictions: They face the same transfer bans, irrevocable proxies, and no-solicitation rules as the Korsana holders.

Why it matters: These agreements de-risk the merger for the companies. They secure the necessary votes from the most influential owners, making it extremely likely the deal will get shareholder approval.

💰 The Financing: Securities Purchase Agreement (EX-10.3)

This is the cash component. Korsana is raising money from new investors to fund operations and the merger process.

• What's Being Sold: New shares of Korsana Common Stock and/or Pre-Funded Warrants (a right to buy stock later, often used for tax or regulatory reasons).
• Purchase Price: The per-share price is called the "Share Price." The per-warrant price is the "Pre-Funded Warrant Price."
• Investors: A group listed in "Exhibit A" (confidential). The agreement requires at least one major investor to commit at least $30 million for the "Investor Majority" threshold to be met.
• Key Condition: The entire purchase is contingent on the Merger Agreement being in effect at closing. The investors are funding the deal with the expectation the merger will complete.

Why it matters: This provides the new Korsana (the post-merger company) with fresh capital to operate and grow. It shows there are sophisticated investors betting on the success of this new entity.

📅 Key Dates & Timeline

• April 1, 2026: Date all agreements are signed.
• "First Effective Time": The moment the first step of the merger legally happens. All the shareholder support agreements terminate at this moment because their job (securing the vote) is done.
• "Expiration Date": The earliest of: the merger closing, the termination of the main Merger Agreement, or a mutual agreement to end the support deals.

⚖️ What This Signals & The Path Ahead

👍 Strengths & Positives:

• Strong Deal Certainty: The support agreements significantly reduce the risk of the merger failing due to a lack of shareholder approval.
• Financing Secured: The simultaneous securities purchase brings in necessary capital, addressing a key operational need for the combined company.
• Clean Structure: The two-step merger is a standard legal mechanism to simplify the final corporate structure.

⚠️ Risks & What to Watch For:

• Regulatory Approval: The deal still requires approval from government bodies (like the FTC or FDA, depending on the business).
• Merger Agreement Conditions: The deal can still collapse if other conditions in the main Merger Agreement aren't met.
• Execution Risk: The core challenge—successfully integrating two biotech companies and advancing their combined drug pipeline—remains after the legal paperwork is done.

🧠 The Analogy

Imagine two houses (Cyclerion and Korsana) are combining into one household. To make it happen smoothly:

1. The most important residents of each house (the shareholders) have signed unbreakable leases promising to support the move and not move out (Support Agreements).
2. They've also lined up a cash advance from a relative (the Investors via the Securities Purchase Agreement) to cover moving costs and renovations. Now, they just need the city's approval (regulators) to make it official.

📇 Key Contacts & People

The agreements are signed by authorized officers of the companies, but specific names and contact details are not provided in this filing excerpt. The "Notices" sections refer to addresses designated in the main Merger Agreement, which is not included here. The individual shareholders signing the support agreements are identified only by confidential Appendix A.

🧩 Final Takeaway

This filing shows the legal scaffolding being erected for Cyclerion's transformation into Korsana. It transforms a headline deal into binding commitments, securing shareholder votes and new cash to pave the way for the new Korsana Biosciences to begin trading. The hardest part—running the business—is next.